ENTITY
WuXi XDC Cayman

WuXi XDC Cayman (2268 HK)

122
Analysis
Health CareChina
WuXi XDC Cayman Inc. operates as a leading contract testing, development and manufacturing organization focused on the global antibody drug conjugates and broader bioconjugate market. The Company provides bioconjugation discovery, analytical development, intermediate and conjugation manufacturing, and other services. WuXi XDC Cayman provides its services worldwide.
more
bullishWuXi XDC Cayman
01 Nov 2023 08:55

Pre-IPO WuXi XDC (PHIP Updates) - Some Points Worth the Attention

WuXi XDC’s share price could perform well due to positive sentiments on ADC.But if the real market size of ADC is much smaller than PD...

Logo
540 Views
Share
bullishWuXi XDC Cayman
31 Oct 2023 16:21

WuXi XDC IPO: The Bull Case

The bull case rests on large addressable markets, market share gains, fast-paced revenue growth, strong revenue visibility, a solid balance sheet...

Logo
603 Views
Share
bullishWuXi XDC Cayman
31 Oct 2023 11:00

WuXi XDC Cayman Pre-IPO - PHIP Updates - Margins Remain Depressed Although Growth Still Strong

WuXi XDC Cayman Inc (1877628D HK) is looking to raise around US$500m in its upcoming Hong Kong IPO. In this note, we discuss WXDC’s PHIP updates.

Logo
548 Views
Share
29 Oct 2023 08:48

ECM Weekly (29th Oct 2023) - Kokusai, J&T, Midea, Wuxi XDC, Cirrus, Cello World, Honasa, SIA

Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.

Logo
559 Views
Share
bullishWuXi XDC Cayman
26 Oct 2023 09:10

WuXi XDC Pre-IPO - Thoughts on Valuation - While TAM Is Uncertain, Sales and PAT Are Set to Double

WuXi XDC Cayman Inc (1877628D HK) is looking to raise around US$500m in its upcoming Hong Kong IPO. In this note, we discuss our thoughts on...

Logo
638 Views
Share
x